179 related articles for article (PubMed ID: 23942335)
1. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
[TBL] [Abstract][Full Text] [Related]
2. Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study.
Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Joosse A; Schilling B; Nijsten T; Schadendorf D; de Vries E
Cancer Med; 2014 Oct; 3(5):1284-93. PubMed ID: 24935402
[TBL] [Abstract][Full Text] [Related]
3. Treatment with β-blockers and reduced disease progression in patients with thick melanoma.
De Giorgi V; Grazzini M; Gandini S; Benemei S; Lotti T; Marchionni N; Geppetti P
Arch Intern Med; 2011 Apr; 171(8):779-81. PubMed ID: 21518948
[TBL] [Abstract][Full Text] [Related]
4. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
5. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
[TBL] [Abstract][Full Text] [Related]
6. β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.
Lemeshow S; Sørensen HT; Phillips G; Yang EV; Antonsen S; Riis AH; Lesinski GB; Jackson R; Glaser R
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2273-9. PubMed ID: 21933972
[TBL] [Abstract][Full Text] [Related]
7. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
[TBL] [Abstract][Full Text] [Related]
8. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.
Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Wagenius G; Carstensen J; Hansson J
Eur J Cancer; 2013 Aug; 49(12):2705-16. PubMed ID: 23583439
[TBL] [Abstract][Full Text] [Related]
9. Topical beta-blockers and mortality.
Müskens RP; Wolfs RC; Witteman JC; Hofman A; de Jong PT; Stricker BH; Jansonius NM
Ophthalmology; 2008 Nov; 115(11):2037-43. PubMed ID: 18801580
[TBL] [Abstract][Full Text] [Related]
10. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer.
Assayag J; Pollak MN; Azoulay L
Eur J Cancer; 2014 Nov; 50(16):2838-45. PubMed ID: 25204805
[TBL] [Abstract][Full Text] [Related]
11. Stage-specific associations between beta blocker use and prognosis after colorectal cancer.
Jansen L; Hoffmeister M; Arndt V; Chang-Claude J; Brenner H
Cancer; 2014 Apr; 120(8):1178-86. PubMed ID: 24415516
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA
Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600
[TBL] [Abstract][Full Text] [Related]
13. Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study.
Weberpals J; Jansen L; Haefeli WE; Hoffmeister M; Wolkewitz M; Herk-Sukel MPPV; Vissers PAJ; Brenner H
Sci Rep; 2017 Jun; 7(1):2911. PubMed ID: 28588274
[TBL] [Abstract][Full Text] [Related]
14. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
Crocetti E; Mangone L; Lo Scocco G; Carli P
Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
[TBL] [Abstract][Full Text] [Related]
15. Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers.
Pascual-Figal DA; Redondo B; Caro C; Manzano S; Garrido IP; Ruipérez JA; Valdés M
Am J Cardiol; 2008 Dec; 102(12):1711-7. PubMed ID: 19064029
[TBL] [Abstract][Full Text] [Related]
16. Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study.
McCourt C; Coleman HG; Murray LJ; Cantwell MM; Dolan O; Powe DG; Cardwell CR
Br J Dermatol; 2014 Apr; 170(4):930-8. PubMed ID: 24593055
[TBL] [Abstract][Full Text] [Related]
17. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.
Joosse A; Collette S; Suciu S; Nijsten T; Patel PM; Keilholz U; Eggermont AM; Coebergh JW; de Vries E
J Clin Oncol; 2013 Jun; 31(18):2337-46. PubMed ID: 23690423
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study.
Golger A; Young DS; Ghazarian D; Neligan PC
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):442-7. PubMed ID: 17515502
[TBL] [Abstract][Full Text] [Related]
19. Conditional survival of malignant melanoma in The Netherlands: 1994-2008.
van der Leest RJ; van Steenbergen LN; Hollestein LM; de Vries E; Nijsten T; van Akkooi AC; Janssen-Heijnen ML; Coebergh JW
Eur J Cancer; 2014 Feb; 50(3):602-10. PubMed ID: 24262585
[TBL] [Abstract][Full Text] [Related]
20. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy C; Young JB;
Am Heart J; 2007 Jan; 153(1):82.e1-11. PubMed ID: 17174643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
